Emergent Drug Patent Portfolio

Emergent owns 1 orange book drug protected by 8 US patents Given below is the list of Emergent's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10085937 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9211253 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9468747 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9480644 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9561177 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9629965 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9707226 Nasal drug products and methods of their use 16 Mar, 2035
Active
US9775838 Nasal drug products and methods of their use 16 Mar, 2035
Active


Given below is the list of recent legal activities going on the following drug patents of Emergent.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 17 Apr, 2024 US9480644
Payment of Maintenance Fee, 8th Year, Large Entity 31 May, 2023 US9211253 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 16 Mar, 2022 US10085937
Review Certificate Mailed 24 Aug, 2021 US9629965
Review Certificate Mailed 23 Aug, 2021 US9211253 (Litigated)
Review Certificate 05 Aug, 2021 US9211253 (Litigated)
Review Certificate 05 Aug, 2021 US9629965
Payment of Maintenance Fee, 4th Year, Large Entity 17 Mar, 2021 US9775838
Payment of Maintenance Fee, 4th Year, Large Entity 06 Jan, 2021 US9707226
Payment of Maintenance Fee, 4th Year, Large Entity 25 Sep, 2020 US9629965
Termination or Final Written Decision 21 Aug, 2020 US9211253 (Litigated)
Termination or Final Written Decision 21 Aug, 2020 US9629965
Payment of Maintenance Fee, 4th Year, Large Entity 23 Jul, 2020 US9561177
Payment of Maintenance Fee, 4th Year, Large Entity 16 Apr, 2020 US9480644
Request for Trial Denied 16 Oct, 2019 US9775838


Emergent's Drug Patent Litigations

Emergent's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 19, 2019, against patent number US9561177. The petitioner Nalox-1 Pharmaceuticals, LLC et al., challenged the validity of this patent, with Opiant Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Emergent's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9211253 February, 2019 Final Written Decision
(21 Aug, 2020)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9468747 February, 2019 Final Written Decision
(21 Aug, 2020)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9629965 February, 2019 Final Written Decision
(21 Aug, 2020)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9775838 February, 2019 Institution Denied
(16 Oct, 2019)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9629965 February, 2019 Institution Denied
(01 Oct, 2019)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9468747 February, 2019 Institution Denied
(09 Sep, 2019)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9211253 February, 2019 Institution Denied
(27 Aug, 2019)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.
US9561177 February, 2019 Institution Denied
(27 Aug, 2019)
Opiant Pharmaceuticals, Inc. Nalox-1 Pharmaceuticals, LLC et al.


Emergent's Family Patents

Emergent drugs have patent protection in a total of 15 countries. It's US patent count contributes only to 48.9% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Emergent Drug List

Given below is the complete list of Emergent's drugs and the patents protecting them.


1. Narcan

Narcan is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10085937 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9211253 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9468747 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9480644 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9561177 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9629965 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9707226 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active
US9775838 Nasal drug products and methods of their use 16 Mar, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Narcan's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List